Girnita Diana M, Burckart Gilbert, Zeevi Adriana
Department of Pathology, Thomas E Starzl Transplant Institute, University of Pittsburgh, Pittsburgh, PA 15213, United States.
Curr Opin Immunol. 2008 Oct;20(5):614-25. doi: 10.1016/j.coi.2008.08.002. Epub 2008 Aug 28.
Consolidating the information that we have on pharmacogenetics and on cytokine genetics to produce patient-oriented individualized drug regimens is an important challenge in transplantation medicine. Using a multi-variant approach based on genetic profile and other relevant clinical factors a score system may be developed to predict the severity of rejection, infection, or other complications associated with transplantation. The ultimate goal of these studies is to improve patient outcome through individualized drug regimens.
整合我们在药物遗传学和细胞因子遗传学方面的信息，以制定以患者为导向的个性化药物治疗方案，是移植医学面临的一项重大挑战。基于基因谱和其他相关临床因素，采用多变量方法，或许可以开发出一个评分系统，以预测与移植相关的排斥反应、感染或其他并发症的严重程度。这些研究的最终目标是通过个性化药物治疗方案改善患者的治疗效果。
